News
Rigenerand commences 3D bioreactor development for cGMP extracellular vesicle exosomes (EV) production
Rigenerand SRL, the biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology, announces it has commenced development of a novel 3D bioreactor and pipeline, specifically designed for the incremental...
News
Kodak announces initiative to create Kodak Pharmaceuticals
Eastman Kodak Company received a $765 million loan from the United States International Development Finance Corporation (DFC) to support the launch of Kodak Pharmaceuticals, a new arm of the company that will produce critical pharmaceutical components, the DFC and...
News
SEKISUI Diagnostics Invests £14.4 Million in cGMP Biopharma CDMO Capacity
Sekisui announces the decision to invest £14.4 Million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent to be completed by the second half of 2022. This investment follows the...
News
Thermo Fisher Expands Model Options for SampleManager LIMS
Thermo Fisher Scientific has expanded deployment model options for SampleManager LIMS software, offering laboratories support of the software deployment in the Amazon Web Services (AWS) Cloud.
Under a contract agreement, Thermo Fisher will manage the deployment process from installation and...
News
Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate
Pfizer Inc and BioNTech SE announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and regulatory approval, beginning...
News
Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
Sanofi and GSK are in advanced discussions, with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine. The vaccine candidate developed by Sanofi in partnership with GSK, is based on the...
News
Over 300 Clinical Studies Benefit from CluePoints COVID-19 Risk Management Support
CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, announced the success of its complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trials. Launched in April in the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
